Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Shanghai HEP Pharmaceutical Co., Ltd.

Clinical trials sponsored by Shanghai HEP Pharmaceutical Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New hope for hepatitis d: experimental drug enters final testing phase Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1 Not yet finished but already full! 1

New drug shows promise against rare liver infection

Disease control Ongoing

This Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the v…

Phase 2 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:06 UTC